A randomized, double-blind, dose ranging, dose comparison-controlled trial to determine the safety and efficacy of BMS298585 in subjects with type 2 diabetes
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Muraglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 29 Sep 2006 Status change
- 14 Feb 2006 New trial record.